GLUCOPHAGE XR Drug Patent Profile

Which patents cover Glucophage Xr, and when can generic versions of Glucophage Xr launch?

Glucophage Xr is a drug marketed by Emd Serono Inc and is included in one NDA.

The generic ingredient in GLUCOPHAGE XR is metformin hydrochloride. There are forty-nine drug master file entries for this compound. Eighty-two suppliers are listed for this compound. Additional details are available on the metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Glucophage Xr

A generic version of GLUCOPHAGE XR was approved as metformin hydrochloride by CHARTWELL on January 24^th, 2002.

Summary for GLUCOPHAGE XR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	352
Patent Applications:	38
Drug Prices:	Drug price information for GLUCOPHAGE XR
DailyMed Link:	GLUCOPHAGE XR at DailyMed

See drug prices for GLUCOPHAGE XR

Recent Clinical Trials for GLUCOPHAGE XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
China National Center for Cardiovascular Diseases	PHASE4
James Wang	Phase 1
United States Department of Defense	Phase 1

See all GLUCOPHAGE XR clinical trials

US Patents and Regulatory Information for GLUCOPHAGE XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-001	Oct 13, 2000		DISCN	Yes	No
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-004	Apr 11, 2003		DISCN	Yes	No

Expired US Patents for GLUCOPHAGE XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-001	Oct 13, 2000
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-001	Oct 13, 2000
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-004	Apr 11, 2003
Emd Serono Inc	GLUCOPHAGE XR	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021202-004	Apr 11, 2003

International Patents for GLUCOPHAGE XR

See the table below for patents covering GLUCOPHAGE XR around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	9908911
Indonesia	26082
Japan	4523153
European Patent Office	1063973	SYSTEME D'APPORT A LIBERATION LENTE BIPHASIQUE DESTINE A DES MEDICAMENTS A SOLUBILITE ELEVEE ET PROCEDE ASSOCIE (BIPHASIC CONTROLLED RELEASE DELIVERY SYSTEM FOR HIGH SOLUBILITY PHARMACEUTICALS AND METHOD)
African Regional IP Organization (ARIPO)	1224	Biphasic controlled release delivery system for high solubility pharmaceuticals and method.

Supplementary Protection Certificates for GLUCOPHAGE XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1412357	77 5006-2008	Slovakia		PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408
2498758	301040	Netherlands		PRODUCT NAME: METFORMINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; SAXAGLIPTINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1401 20191113
2498758	132020000000034	Italy		PRODUCT NAME: METFORMINA O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE; SAXAGLIPTIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE; DAPAGLIFLOZIN O UN SUO SOLVATO FARMACEUTICAMENTE ACCETTABILE.(QTRILMET); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1401, 20191113
1506211	92496	Luxembourg		PRODUCT NAME: COMBINAISON DE DAPAGLIFLOZINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DE METFORMINE OU D UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,TELLE QUE PROTEGEE PAR LE BREVET DE BASE EP1506211 B1
1506211	PA2014026	Lithuania		PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116

Market Dynamics and Financial Trajectory for Glucophage XR

Last updated: January 9, 2026

Executive Summary

Glucophage XR (Extended-Release formulation of metformin) is a pivotal product in type 2 diabetes management, enjoying widespread clinical adoption since its introduction. The drug's market is influenced by factors encompassing global diabetes prevalence, regulatory policies, competitive dynamics, and evolving healthcare priorities such as personalized medicine. This analysis provides a comprehensive overview of the current market environment, projected financial trajectories, and key drivers shaping the future of Glucophage XR. It combines recent sales data, regulatory insights, and competitive landscape assessments to serve as a strategic resource for stakeholders in pharmaceutical, investment, and healthcare sectors.

---

What Are the Market Drivers for Glucophage XR?

Global Diabetes Epidemic

The rising prevalence of type 2 diabetes is a central factor impacting Glucophage XR's market. According to the International Diabetes Federation (IDF), approximately 537 million adults lived with diabetes in 2021, a figure projected to reach 643 million by 2030[1]. Approximately 85-90% of these cases are type 2 diabetes, which is predominantly managed with metformin-based therapies, including Glucophage XR.

Clinical Advantages of Extended-Release Formulation

Compared to immediate-release formulations, Glucophage XR offers benefits such as:

• Reduced gastrointestinal side effects
• Improved patient adherence
• Simplified dosing schedules (once daily)

These factors make Glucophage XR particularly appealing for long-term management, fostering consistent market demand.

Evolving Treatment Guidelines

Leading endocrinology associations, including the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD), recommend metformin as first-line therapy, emphasizing early initiation of extended-release options[2]. This endorsement sustains demand across demographics and healthcare systems.

Healthcare Policy and Reimbursement Trends

Government and insurer reimbursement policies increasingly favor cost-effective treatments like Glucophage XR, especially in value-based care models. These policies catalyze adoption and influence market penetration.

---

How Is the Competitive Landscape Shaping Glucophage XR’s Market Share?

Major Competitors and Alternatives

Brand/Product	Formulation	Market Share (Estimate)	Key Features
Glucophage XR (Merck)	Extended-Release	~35-40% (global)	Once daily, favorable GI profile
Glucophage (immediate-release metformin)	Immediate-release	Dominant, but declining	Cost-effective, common in generic form
Other Generics	Various	~25-30%	Lower-cost options, variable efficacy
Novel formulations (e.g., combination pills, new delivery methods)	Various	Emerging (~10%)	Addressing specific patient needs

Patent Expiry and Generic Entry

Most formulations of metformin, including Glucophage XR, face patent expiration timelines (patents typically expired or expiring in the early 2020s in major markets). This has spurred a surge in generic versions, exerting downward pressure on prices but expanding access.

Regional Market Penetration

Region	Market Penetration (%)	Drivers	Challenges
North America	High (~60-70%)	Strong healthcare infrastructure, guidelines	Price competition from generics
Europe	Moderate (~50-65%)	Reimbursement policies, economic factors	Regulatory variability
Asia-Pacific	Growing (~40-55%)	Expanding diabetes prevalence, urbanization	Fragmented healthcare systems
Latin America	Emerging (~30-45%)	Increasing healthcare access	Limited healthcare infrastructure

Regulatory and Pricing Policies

Regulatory agencies like the FDA, EMA, and national authorities endorse generics, affecting branded product sales. Price negotiations and formulary restrictions have led to decreasing per-unit revenue in some markets, though overall volume remains robust.

---

What Is the Financial Trajectory of Glucophage XR?

Revenue Trends and Projections

Year	Estimated Global Sales (USD billions)	Growth Rate (CAGR)	Remarks
2021	~$1.2 billion	—	Stabilized after initial growth phase
2022	~$1.3 billion	8-10%	Driven by rising global prevalence
2023	~$1.4 billion	7-9%	Market expansion, new regional entries
2024-2028	Projected CAGR of 5-7%	—	Assuming sustained generic competition, policy influences

(SOURCE: IQVIA, 2022; MarketWatch, 2023)

Key Revenue Factors

• Pricing Dynamics: While average wholesale prices (AWP) are declining due to generics, volume growth offsets revenue decline.
• Market Expansion: Entry into emerging markets and increased prescription issuance contribute to revenue stability.
• Formulation Diversification: Development of fixed-dose combinations and biosimilars may influence future sales channels.

Cost Considerations

• Patent expirations led to increased generic competition, influencing pricing strategies.
• Manufacturing costs for Glucophage XR are relatively stable, with economies of scale benefiting large-volume producers.
• R&D investment for new formulations and indications remains modest compared to the base product.

Strategic Outlook

Scenario	Assumptions	Implication
Optimistic Growth	Policy support, higher adherence, emerging markets expansion	Revenue CAGR ~6-8% post-2024
Conservative	Price erosion, competitive pressures, regulatory hurdles	Stabilization or slight decline in revenues
Innovation-Driven	New formulations or combination therapies gaining approval	Potential to recombinant growth

---

How Do Policy and Market Trends Impact Long-Term Financials?

Regulatory Influences

• Generic Policies: Streamlined approval for generics enhances availability, reducing revenue per unit but maintaining volumes.
• Price Regulations: Price caps in many countries, especially in Europe and Asia, compress profit margins.
• Reimbursement Policies: Shift towards value-based care incentivizes generic use but limits pricing flexibility.

Healthcare System Trends

• Early diagnosis and increased screening expand the target patient pool.
• Digital health tools improve treatment adherence, potentially increasing prescription longevity.
• Public health initiatives against diabetes emphasize lifestyle modifications, possibly affecting pharmacotherapy demand.

---

What Are the Key Market Challenges and Opportunities?

Challenges	Opportunities
Price erosion from generics	Expansion into emerging markets
Regulatory hurdles in developing countries	Formulation innovations (e.g., fixed-dose combos)
Competition from novel anti-diabetic agents (e.g., SGLT2 inhibitors, GLP-1 receptor agonists)	Positioning Glucophage XR as foundational therapy alongside newer agents
Patent expiration and patent cliffs	Cost leadership and volume-driven growth

---

How Does Glucophage XR Compare Versus Other Low-Cost Diabetic Medications?

Parameter	Glucophage XR	SGLT2 Inhibitors / GLP-1 Agonists	DPP-4 Inhibitors
Cost	Moderate to low (~$4-10/day in US generics)	High (~$300-500/month)	Moderate (~$100-200/month)
Efficacy	Proven glycemic control	Superior cardiovascular and renal benefits	Effective glycemic control
Side Effect Profile	GI, lactic acidosis risk (rare)	Genital infections, ketoacidosis	Slightly better tolerated
Position in Therapy	First-line, foundational	Adjunct/add-on	Add-on, second-line

---

Conclusions: Market and Financial Outlook for Glucophage XR

1. Sustained Core Demand: The entrenched position of metformin as first-line therapy ensures consistent baseline demand, reinforced by updated treatment guidelines and chronic disease prevalence.
2. Revenue Resilience Amid Competition: While patent expirations and generics pressure lower margins, high volumes and market expansion in emerging economies offset declines.
3. Potential Growth Drivers: Innovation in formulations, combination therapies, and strategic regional expansion underpin future growth trajectories.
4. Price Sensitivity: Policymaker and payer dynamics necessitate cost-effective pricing strategies to maintain competitiveness.
5. Long-Term Risks: Competition from novel agents, regulatory newness, and off-label prescribing trends could influence sales patterns.

---

Key Takeaways

• Market size for Glucophage XR is projected to grow at a CAGR of approximately 5-7% globally until 2028, driven chiefly by rising diabetes prevalence.
• Generic competition has significantly impacted pricing, but volume growth sustains overall revenue.
• Emerging markets represent a major opportunity, with greater access to affordable metformin formulations.
• Formulation innovations and strategic partnerships could safeguard market share against newer antidiabetic therapies.
• Regulatory and policy environments remain critical; companies need adaptive strategies to navigate evolving reimbursement landscapes.

---

FAQs

1. How much of Glucophage XR's revenue is impacted by patent expiry?

Patent expirations in early 2020s have encouraged generic competition, reducing per-unit prices by 30-50%. Despite this, high prescription volumes, especially in developing countries, sustain revenue levels.

2. Are there significant regulatory hurdles that could hinder Glucophage XR’s market growth?

Regulatory agencies generally endorse generic formulations. However, regional differences in approval processes and pricing regulations can create delays or restrict market access.

3. What are the primary barriers to entry in the Glucophage XR market?

High development costs, regulatory approval processes, established presence of generics, and price competition are barriers. Nonetheless, regional market expansion remains feasible through strategic alliances.

4. How does Glucophage XR compare to newer diabetic drugs in terms of market share?

Despite newer agents offering additional benefits, Glucophage XR remains the first-line treatment due to cost and extensive clinical evidence, accounting for roughly 40% of oral anti-diabetic prescriptions globally.

5. What future innovations might influence Glucophage XR’s market position?

Potential innovations include fixed-dose combination pills, new delivery methods, and personalized treatment plans leveraging digital health, all of which could enhance adherence and expand usage.

---

References

[1] International Diabetes Federation. (2021). IDF Diabetes Atlas, 9th edition.
[2] American Diabetes Association. (2022). Standards of Medical Practice: 2022.
[3] IQVIA. (2022). Global Organon Report.
[4] MarketWatch. (2023). Diabetes Medication Market Analysis.

Note: All figures and projections are estimates based on published industry data and market analysis as of 2023.